AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2021
Jun 26, 2021
31071_dirs_2021-06-25_94b56223-19e8-4f2a-94b5-917d718cf80b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2021-06-24
Reporting Person: De Backer Marianne (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-24 | Common Stock | S | 5000 | $89.85 | Disposed | 21500 | Direct |
Footnotes
F1: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.76 to $90.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.